ACLX
Arcellx, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
16.06
P/S
301.16
EV/EBITDA
-33.98
DCF Value
$0.99
FCF Yield
-3.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
-64.8%
Operating Margin
-1135.6%
Net Margin
-1027.3%
ROE
-55.4%
ROA
-37.9%
ROIC
-49.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $1.7M | $-58.1M | $-1.00 |
| FY 2025 | $22.3M | $-228.9M | $-4.07 |
| Q3 2025 | $4.9M | $-55.8M | $-0.99 |
| Q2 2025 | $7.6M | $-52.8M | $-0.94 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.25
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.